SLC5A2 and diabetes mellitus: Even in type 1 diabetes mellitus, dapagliflozin also reduced MAGE in a dose dependent manner [15], which provided evidence of the beta-cell independent effect of SGLT2 inhibitors on glucose fluctuation.